1-1 of 1
Brecher Mark, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Low Incidence of GVHD and Treatment-Related Morbidity (TRM) with Intermediate Doses of Continuous Infusion IV Busulfan and Daily Fludarabine with Individualized Doses of Alemtuzamab for Matched Related (MRD) and Unrelated (MUD) Transplant Pts with High-Risk Hematologic Malignancies.

Thomas Shea, MD, Jonathan Serody, MD, PhD, Don Gabriel, MD, PhD, Terrance Comeau, MD, Anastasia Ivanova, PhD, Dominic Moore, PhD, Robert Irons, PA, Whitley Julia, BS, Sharf Andrew, RN, Cherie Dunphy, MD, Brecher Mark, MD
Journal: Blood
Blood (2007) 110 (11): 4940.
https://doi.org/10.1182/blood.V110.11.4940.4940
Published: 2007